Using peripheral blood indicators and T cells subsets to evaluate the efficacy of immunotherapy for advanced and recurrent cervical cancer

T-cells with post-treatment normalization of immune markers (increased T-cells, decreased PD-1+ cells, and tumor antigens) are associated with a higher likelihood of benefiting from immunotherapy. It should be noted that this study has limitations, including a modest sample size and the assessment of biomarkers at only a single post-treatment time point, which may affect the generalizability of the findings. These peripheral blood biomarkers may represent a minimally invasive approach for exploring treatment dynamics and are considered worthy of further investigation as potential adjuncts in the context of personalized immunotherapy for advanced cervical cancer. However, their predictive performance and clinical utility remain to be validated in larger, independent cohorts before any clinical application can be considered.